You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay

    SBC: Immuno-mycologics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is a chronic infectious disease that infects approximately one third of the worldandapos s population Eighty five percent of the estimated million new cases of TB in occurred in resource limited countries located in Asia and Africa In there were million deaths from TB among HIV negative patients and additional TB d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Light Visor for Treating Jet Lag: Controlled Field Trial

    SBC: Bio-Brite, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Jet lag is a syndrome of behavioral, cognitive, and physical symptoms that result when travelers are exposed to a sudden shift of the day-night cycle. These symptoms impact on alertness and performance of airline and military personnel and the safety of the traveling public. They may also exacerbate medical and psychiatric illness, and frequent flyers may face ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Imaging & Localizing Device Using the Barkhausen Effect

    SBC: Biomed Innovations, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This application proposes a new method for imaging medical devices that can contain amorphous ferromagnetic materials. Potential devices include Fiducial markers, surgical clips, catheters, and brachytherapy-seeds. The procedure would not require radioactive materials and would be relatively insensitive to inhomogeneities. Small array- or stereologic-detecto ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  7. Parallel Assays for Anti-Ro Peptide Diagnostics

    SBC: JK AUTOIMMUNITY, INC.            Topic: N/A

    DESCRIPTION (provided by the applicant): Diagnosis of rheumatic diseases is inefficient, time consuming, and frustrating. Indeed, many patients suffer unnecessarily. We wish to develop a parallel assay system for the serology of autoimmune rheumatic diseases involving multiple analytes (on the order of 1,500 per assay performed) by concentrating upon the anti-Ro autoantibody system. Anti-Ro is as ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  8. Immune Attack: Simulation Game for Adolescent Education

    SBC: SIMQUEST INTERNATIONAL, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This research project will develop an engaging game for high school students using simulation of immune cells in the human body fighting infection. The approach combines visually stunning 3D graphics and advanced training technologies including automated case scenario generation, intelligent tutoring, automated debriefing, live conferencing, and performance ass ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  9. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government